Epoprostenol treatment for idiopathic pulmonary arterial hypertension in pregnancy.
Idiopathic pulmonary arterial hypertension is a rare condition associated with significant maternal mortality. We report the management of a 37-year-old multigravida with severe disease using epoprostenol, a multidisciplinary approach, and a planned delivery. Although the patient survived the pregnancy, her pulmonary function significantly worsened. Epoprostenol, a pulmonary vasodilator, should be considered when indicated during pregnancy. Neither fetal nor neonatal harm was identified.
Garabedian
M J
MJ
Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY, USA. matt.garabedian@uky.edu
Hansen
W F
WF
Gianferrari
E A
EA
Lain
K Y
KY
Fragneto
R Y
RY
Campbell
C L
CL
Booth
D C
DC
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D017604:Cesarean Section, Repeat; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010348:Patient Care Team; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*
D000959:Antihypertensive Agents; D011464:Epoprostenol